Processa Pharmaceuticals, Inc.. Common
$2.60 -$0.27 (-9.41%) 1D After hours
Processa Pharmaceuticals, Inc.. Common
Key Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 26
From its Apr 16 high, the share price fell 42%.
Peak close $3.18 on Apr 16; trough close $1.86 on Jun 26. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -42% -
May 14
The stock moved +20.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 14 -
Mar 19
The stock moved -26.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 19
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Processa Pharmaceuticals, Inc.. Common
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.